Nearly 5 million asthmatics could benefit from antifungal therapy

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from The University of Manchester and the University of Toronto.

Their work, published today in the journal Medical Mycology, has also re-estimated the total number of worldwide – to reveal a staggering 193 million sufferers. Twenty-four million live in the United States, 20 million each in India and China, and seven million in the United Kingdom.

Clinical studies have shown that oral significantly improve symptoms and in asthmatics with ABPA, treatment endorsed by the Cochrane Collaboration. This is the first time that a global estimate of ABPA numbers has been made.

In national league tables of asthma rates in adults, only Australia and Sweden have a higher prevalence than the UK. In global league tables of ABPA occurrence, New Zealand tops the list with a 3.5% rate in new patients attending chest clinics at hospitals. The rates were 2.6% in Cape Town, 2.3% in Saudi Arabia, 2.5% in China and 0.7% in an older study from Ireland. No population-based studies have been done.

In addition to standard , the antifungal therapy used is itraconazole – now a generic, inexpensive antifungal – with a response rate of 60%. The researchers also found that antifungal therapy also benefits patients with severe asthma sensitized to fungi, called SAFS.

Alternatives include voriconazole and posaconazole, which have 75-80% response rates. In a recent assessment of and posaconazole for both ABPA and SAFS, 75% of patients were able to stop taking , a major benefit, and 38% of patients had their asthma severity downgraded on antifungal therapy.

Professor David Denning, Professor of Medicine and Medical Mycology at The University of Manchester and Director of the University Hospital of South Manchester's National Aspergillosis Centre, led the study into the total number of asthmatics worldwide. He said the study results implied that asthma admissions and deaths could be avoided with more extensive use of antifungal therapy.

"We were surprised by the number of patients with ABPA, and by the lack of community based studies done," he said. "Our National Aspergillosis Centre treats hundreds of these patients each year, generally with major improvement, and so a conscious program to seek out ABPA from all asthmatics is required."

More information: To view the paper entitled, "Global burden of asthma in adults and ABPA," click here: (www.ncbi.nlm.nih.gov/pubmed/23210682)

add to favorites email to friend print save as pdf

Related Stories

Drug resistance fears over killer fungal disease

Jul 16, 2009

(PhysOrg.com) -- Treatments for the most common airborne fungal disease are proving less effective due to increased resistance to the anti-fungal drugs used to combat infections.

Drug-resistance fears for deadly fungal disease

May 05, 2011

Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.

Recommended for you

Study reveals nervous system's role in asthma attacks

5 hours ago

(Medical Xpress)—Asthma is a debilitating condition that kills 250,000 people around the world each year. People with asthma have hyperreactive airways and thickened lung walls obstructed with mucus. During ...

New diagnostic test to distinguish psoriasis from eczema

Jul 10, 2014

In some patients, the chronic inflammatory skin diseases psoriasis and eczema are similar in appearance. Up to now, dermatologists have therefore had to base their decision on which treatment should be selected on their own ...

New drugs to combat asthma and the like

Jul 01, 2014

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.

User comments